- 英文名称
- Atosiban
- 分子式
- C43H67N11O12S2
- 分子量
- 994.19
- 中文别名
- (S)-N-((S)-5-氨基-1-((2-氨基-2-氧代乙基)氨基)-1-氧代戊烷-2-基)-1-((4R,7S,10S,13S,16R)-7-(2-氨基-2-氧代乙基)-13-((S)-仲丁基)-16-(4-乙氧基苄基)-10-((R)-1-羟乙基)-6,9,12,15,18-五氧代-1,2-二硫代-5,8,11,14,17-五氮杂环二十烷-4-羰基)吡咯烷-2-甲酰胺; (S)-N-((S)-5-Amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-((S)-sec-butyl)-16-(4-ethoxybenzyl)-10-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide; 1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin; antocin; 1-deamino-2d-tyr-(oet)-4-thr-8-orn-oxytocin; Tractocile; 1-({(4R,7S,10S,13S,16R)-7-(2-Amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-(4-ethoxybenzyl)-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-ornithylglycinamide; 1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin; 1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineoxytocin; [Mpr-D-Tyr(OEt)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2; 1-({(4R,7S,10S,13S,16R)-7-(2-Amino-2-oxoethyl)-13-[(2S)-2-butanyl]-16-(4-ethoxybenzyl)-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-ornithylglycinamide; RW-22164; RWJ-22164; oxytocin,1-(3-mercaptopropanoicacid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l
- 用途
- 作为缩宫素与加压素V1A联合受体拮抗剂，竞争性结合缩宫素和加压素V1A受体，阻断其作用途径，减少子宫收缩；用于自发早产的研究；是子宫内及蜕膜、胎膜上环状肽催产素受体竞争性拮抗剂。
